SAN

80.42

+0.05%↑

SAN

80.42

+0.05%↑

SAN

80.42

+0.05%↑

SAN

80.42

+0.05%↑

SAN

80.42

+0.05%↑

Search

Vetoquinol SA

Open

SectorHealthcare

86.9 0.12

Overview

Share price change

24h

Current

Min

85.1

Max

87.5

Key metrics

By Trading Economics

Income

25M

Sales

258M

P/E

Sector Avg

16.569

84.243

Dividend yield

1.02

Profit margin

9.734

Employees

2,497

EBITDA

48M

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.02%

2.28%

Next Earnings

27 mar 2026

Market Stats

By TradingEconomics

Market Cap

1B

Previous open

86.78

Previous close

86.9

News Sentiment

By Acuity

25%

75%

45 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Vetoquinol SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 lut 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 lut 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 lut 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 lut 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 lut 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 lut 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 lut 2026, 22:55 UTC

Earnings

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 lut 2026, 22:55 UTC

Earnings

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 lut 2026, 22:55 UTC

Earnings

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 lut 2026, 22:55 UTC

Earnings

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 lut 2026, 22:55 UTC

Earnings

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 lut 2026, 22:55 UTC

Earnings

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 lut 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 lut 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 lut 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 lut 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 lut 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 lut 2026, 02:46 UTC

Acquisitions, Mergers, Takeovers

Big Money, High Anxiety -- Barrons.com

6 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 lut 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6 lut 2026, 21:40 UTC

Acquisitions, Mergers, Takeovers

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 lut 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 lut 2026, 21:17 UTC

Earnings

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 lut 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 lut 2026, 21:14 UTC

Acquisitions, Mergers, Takeovers

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 lut 2026, 21:13 UTC

Earnings

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 lut 2026, 21:13 UTC

Earnings

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 lut 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 lut 2026, 20:34 UTC

Earnings

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer Comparison

Price change

Vetoquinol SA Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

72.6 / 75.1Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

45 / 352 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat